Introduction
The use of protease inhibitors (PIs) as a component of combination antiretroviral therapy (ART) has radically improved the prognosis of HIV infection, leading to significant and durable control with immunorestoration and increasing life expectancy. 1 In the first years of introduction, however, high efficacy was counterbalanced by a large burden of adverse events, such as lipodystrophy, dyslipidemia, and insulin resistance.
2 Atazanavir (Atv) was the first PI prescribed once daily, followed by darunavir (Drv) which proved to be as efficacious as other PIs, but with a better lipid and metabolic profile and a lower rate of lipodystrophy. 3, 4 Recently developed, 
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Squillace et al tenofovir alafenamide (Taf) has been shown to be equally effective and have lower toxicity than tenofovir disoproxil fumarate (TDF). [5] [6] [7] The introduction of single-tablet regimens (STRs) has changed the scenario in the management of HIV infection, significantly increasing adherence and quality of life of people living with HIV. 8 Until last year, STRs were available only for nonnucleoside reverse-transcriptase inhibitors and integrase inhibitors. The newly approved one-pill combination of Drv, cobicistat (Cobi), emtricitabine (2′,3′-dideoxy-5-fluoro-3′-thiacytidine [FTC] ), and tenofovir alafenamide (Taf), being PI-based, thus represents a novelty in HIV therapy. The aim of this review was to evaluate the pharmacokinetics, efficacy, and safety of DrvCobi-FTC-Taf.
Drv-Cobi-FTC-Taf pharmacokinetics Taf
After intestinal absorption, Taf enters hepatocytes by passive diffusion, facilitated by organic anion-transporting polypeptides 1B1 and 1B3. It is then metabolized by carboxylesterase 1 to form tenofovir (Tfv), which phosphorylates to Tfv diphosphate, its active metabolite. 9, 10 Taf is more stable than TDF in plasma: in vitro, the plasma halflife of Taf is 30-90 minutes compared to 0.4 minutes for TDF, allowing for efficient uptake by hepatocytes. 11, 12 Tfv is eliminated through the kidneys by both active proximal tubule secretion and passive glomerular filtration: lowering the administered Tfv equivalents decreases kidney exposure. Incubation of primary human hepatocytes with Taf in vitro shows high intracellular concentrations of Tfv diphosphate, approximately five and 120 times higher than concentrations observed with TDF and Tfv, respectively. Tfv diphosphate has been demonstrated to be a potent inhibitor of HBV replication. 10, 13 In severely hepatically impaired (Child-Pugh C) patients uninfected with HIV treated with Taf 25 mg, Tfv exposure has been reported to be only modestly lower compared to healthy controls with normal hepatic function. 14 In patients with severe renal impairment receiving treatment with Taf 25 mg, plasma levels of Tfv were lower than those historically seen in pharmacokinetic studies using TDF in antiretroviral regimens for HIV-infected patients with normal renal function, albeit higher than in matched healthy subjects.
14 A study on the effect of food on Taf pharmacokinetics showed that Taf exposure decreased in fasting conditions. 15 However, no significant trend in exposure response/safety regarding Taf exposure was found in fasting or fed conditions. 
Drv-Cobi
Like most PIs, Drv is metabolized extensively through CYP3A4 in the liver and the gut. 16 Once-daily administration and lower doses can thus be achieved by coadministering a pharmacokinetic enhancer. Until recently, low-dose ritonavir (Rtv; 100 mg once or twice daily), a strong CYP3A4 and Pgp inhibitor, was the staple pharmacokinetic booster available. 17 However, this enhancement is not limited to antiretroviral drugs, but affects other drugs metabolized through CYP, with risk of side effects. In order to overcome this issue, a new antiretroviral drug booster, Cobi, was developed from the Rtv molecule. Despite being similar to Rtv in many aspects, Cobi inhibits CYP isoenzymes more selectively and does not cause induction effects on glucuronidation or CYP. 18 Furthermore, Cobi has high aqueous solubility and can be readily coformulated with other agents. It is currently used in fixed-dose combinations (FDCs) to enhance plasma concentrations of elvitegravir, Atv, and Drv. Importantly, while Rtv has activity against HIV, possibly leading to the development of drug-resistance mutations to PIs in cases of suboptimal regimens, Cobi is devoid of intrinsic activity against HIV replication. 19, 20 Recently, Drv 800 mg and Cobi 150 mg have become available in an FDC (Rezolsta; Johnson and Johnson, New Brunswick, NJ, USA).
Drv achieves peak plasma concentration (C max ) in 3-4.5 hours after oral administration of Drv-Cobi 800/150 mg. Administration with food significantly increases Drv absorption, raising C max more than double and Drv area under the curve (AUC) up to 1.7-fold (Cobi pharmacokinetics are unaffected). 21, 22 Cobi binds to plasma proteins at up to 98%, and is mostly eliminated through feces (86%). 23 In a study involving healthy volunteers, apparent volume of distribution was 269 and 158 L for Cobi 100 and 200 mg/day, respectively. 24 Cobi has a short median plasma half-life (3-4 hours). 23 In a phase 1, open-label, randomized clinical trial comparing the bioavailability of two distinct Drv-Cobi 800/150 mg oncedaily coformulations and Drv-Rtv 800/100 mg once daily, Drv AUC 24 hours and C max with either enhancer were found to be comparable. 25 In a phase IIIB study of 60 HIV-infected patients, the pharmacokinetic profile of Drv was analyzed by administering Drv 800 mg and Cobi 150 mg (as single agents) with any nucleoside reverse-transcriptase-inhibitor backbone (mostly TDF-based). 26 Mean Drv AUC, C max , and C trough values ± SD were 81,646±26,322 ng⋅h/mL, 7,663±1,920 ng/mL, and 1,311±969 ng/mL, respectively, comparable to results observed in healthy volunteers. 20, 25, 27, 28 Geometric mean values 24 hours after the observed dose for Cobi-boosted Drv were reported to be 43 ng/mL in saliva and 11,878 ng/mL in 
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Drv-Cobi-Ftc-Taf urine. Concentration decay in saliva/urine was found to mirror plasma concentrations. 29 Cobi and Rtv produce comparatively effective Drv concentrations in cerebrospinal fluid. 30 
Drug-drug interactions with Drv-Cobi
As mentioned, Cobi functions primarily as a pharmacokinetic enhancer by means of CYP3A4 inhibition. However, other enzymes and transporters are weakly inhibited by Cobi (see Figure 1) . 20, 21, 27 In comparison to Rtv, Cobi is a more selective CYP3A4 inhibitor, as it is devoid of effects on other isoenzymes. It also lacks the induction activity of Rtv on several enzymes and transporters, including CYP isoenzymes, Pgp, and glucuronyltransferases. 15, 31, 32 Table 1 summarizes the main differences between Rtv and Cobi. 31 Coadministration of Cobi and Pgp substrates (ie, digoxin), may increase the latter drug's plasma levels, possibly leading to adverse events. 33 Conversely, coadministered drugs that inhibit/induce CYP3A4 will affect Cobi plasma concentrations. Cobi concentrations are increased by coadministration with other inhibitors, increasing the risk of toxicity, while in contrast CYP3A inducers may lower Cobi concentrations, possibly leading to the emergence of drug-resistance mutations and virological failure. Importantly, as some nonnucleoside reverse-transcriptase inhibitors, namely etravirine, efavirenz, or nevirapine (but not rilpivirine), can be strong inducers, their coadministration with Cobi is contraindicated. 34 Relevant discrepancies between Cobi and Rtv have been reported for interactions with rifabutin 35, 36 and warfarin. 37 There are no available data on the usage of Cobi as a pharmacokinetic enhancer for PIs other than atazanavir or Drv. Furthermore, the Drv-Cobi combination is not potent enough to boost the activity of other coadministered drugs, such as elvitegravir, meaning that coadministration might pose a risk of suboptimal plasma levels, possibly leading to virological failure.
35,38

Drv-Cobi-FTC-Taf fixed-dose combination pharmacokinetics phase I studies
The phase I trial NCT02578550 confirmed the bioequivalence of FDC Drv-Cobi-FTC-Taf relative to the separate agents (Drv 800 mg tablet formulation and FTC-Taf 200/10 mg FDC) in the presence of 150 mg Cobi under fed conditions in healthy participants (see Table 2 ). The impact of food on the bioavailability of coformulated Drv-Cobi-FTC-Taf was tested in the phase I trial NCT02475135. 39 Food effects with Drv were observed only after administration of Drv-Cobi-FTC-Taf. It is thus recommended that Drv-Cobi-FTC-Taf be taken with food, which is also the recommendation in the ongoing phase III trials. 40 
Efficacy: phase II and III studies
In an exploratory phase II trial (ClinicalTrials.gov NCT01565850; GS-US-299-0102) 41 in 153 treatment-naïve adults with estimated glomerular filtration rate (GFR) $70 mL/min, the virological efficacy of the Drv-Cobi-FTC-Taf regimen was compared to a regimen containing Drv and Cobi combined with FTC and TDF with 2:1 double-blinded randomization (see Table 2 ). 42 At week 24, viral suppression (HIV1 RNA ,50 copies/mL) rates were similar (74.8% for Taf vs 74.0% for TDF; US Food and Drug Administration [FDA] snapshot analysis, primary end point, with a 12% margin for noninferiority). At week 48, however, rates were 76.7% for the Taf-containing STR vs 84.0% for the TDF-containing regimen. This difference appeared to be driven by a higher rate of discontinuations in the Taf (6.8%) vs TDF arm (2%). On the other hand, significant renal and bone safety improvements were observed in the Taf arm. Of note, no resistance to any compound was observed. A single-tablet, once-daily regimen of Drv 800 mg-Cobi 150 mg-FTC 200 mg-Taf 10 mg is currently under investigation in two international, randomized, phase III studies: EMERALD (ClinicalTrials.gov NCT02269917) and AMBER (NCT02431247; see Table 2 ). 43, 44 EMERALD was a randomized, active-controlled, open-label, international, multicenter trial carried out in nine countries in North America and Europe that began on March 30, 2015. 45 The aim of the study was to evaluate safety and efficacy of single-tablet Drv-Cobi-FTC-Taf as a potential switch option 
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Squillace et al for the treatment of HIV1 infection in adults with viral suppression. Treatment-experienced and virologically suppressed (viral load ,50 copies/mL for $2 months) HIV1-infected adults were eligible. One viral load of 50-200 copies/mL was allowed within 12 months before screening, and patients with a history of virological failure on regimens other than Drvcontaining were allowed. Patients were randomly assigned (2:1) to switch to the open-label study regimen or continue the control regimen. The primary outcome was the proportion of participants with virological rebound (either confirmation of viral load $50 copies/mL or premature discontinuation, with last viral load $50 copies/mL). Noninferiority was tested (4% margin) vs the control regimen in the intention-to-treat population. Of 1,141 total patients (763 and 378 in the study and control groups, respectively), 58% had previously received five or more antiretrovirals, including screening drugs, and 15% had experienced previous non-Drv virological failure. The study regimen was found to be noninferior for virological rebound (2.5% patients vs 2.1% in the study and control groups, respectively; difference 0.4%, 95% CI-1.5-2.2; P,0.0001). No accumulation of drug resistance was observed. The proportion of adverse event-related discontinuations (1% in the study group vs 1% in the control group) and grade 3-4 adverse events (7% vs 8%, respectively) was similar between groups. A small, statistically significant (0.2±1.1 vs 0.1±1.1, P=0.010) difference between groups in change from baseline in total:high-density lipoprotein (HDL) cholesterol ratio was reported; however, this difference was not deemed to be clinically relevant. Only one serious adverse event (a case of pancreatitis) was reported to be possibly related to the study regimen.
The purpose of the AMBER study 46 is to demonstrate efficacy noninferiority of a Drv-Cobi-FTC-Taf FDC tablet vs Drv-Cobi FDC coadministered with FTC-TDF in 725 HIV1-infected, ART-naïve adult participants in the context of a multicenter, randomized, double-blind, active-controlled study beginning July 6, 2015. The primary outcome of the study is the percentage of participants obtaining HIV RNA ,50 copies/mL defined by the FDA snapshot approach (time frame: week 48). Unpublished results at week 48 showed the FDC to be noninferior to the combination of DrvCobi and Taf-FTC in terms of efficacy (with 91.4% vs 88.4% patients achieving virological suppression, respectively). 46 Interestingly, neither arm developed Drv, primary PI or TDFTaf Resistance Associated Mutations (RAMs). One patient in the Drv-Cobi-Ftc-Taf arm, however, developed M184I/V, which confers high-level in vitro resistance to lamivudine and FTC while increasing susceptibility to TDF. 47 Few serious adverse events or adverse event-related discontinuations were reported: diarrhea and rash were the most commonly reported adverse events in both arms. 
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Drv-Cobi safety
Available data regarding Drv-Cobi 800/150 mg once-daily combination safety and tolerability reveal mild adverse events, due to gastrointestinal disturbances (diarrhea, nausea, flatulence) and rash or other skin reaction. 26 During the Drv clinical development program, severe skin reactions were occasionally described, while in the postmarketing phase grade acute skin reactions were at times reported. Caution must be taken with patients with past hypersensitivity reactions during sulfonamide use, because of the reported higher probability of developing the same adverse event with Drv.
21,26
The updated unpublished AMBER study reported the tolerability profile of Drv-Cobi-FTC-Taf at 48 weeks to be good (randomized double-blind phase: Drv-Cobi-FTC-Taf matched with TDF-FTC + Drv-Cobi placebo vs TDF-FTC + Drv-Cobi matched with Drv-Cobi-FTC-Taf placebo), with no discontinuations due to renal, bone, or central nervous system adverse events. 46 Cobi inhibits human renal transporters (see Figure 1) . 48 Because of those inhibitions in urinary creatinine excretion, an increase in creatinine plasma concentration of 0.05-0.1 mg/dL and a parallel GFR reduction of 10 mL/min are expected within the first 4 weeks after Cobi introduction, with stabilization occurring during treatment and resolving with Cobi discontinuation, with no effect on actual clearance. 49, 50 Drv-Cobi was also studied in patients with no severe renal impairment in the GS-US-236-118 Study, which showed stable estimated GFR (eGFR; measured by cystatin C) at week 96. 51 The metabolic profile of DrvCobi-FTC-Taf observed at 48 weeks in the EMERALD 45 and AMBER studies revealed significant increases in total cholesterol, low-density lipoprotein (LDL) cholesterol, and total cholesterol:HDL-cholesterol ratio, with no significant increase in lipid-lowering therapy prescription in the study arm. These results were partially attributable to the process of comparing Taf vs TDF in both studies, given the former's relative lack of lipid-lowering effect. 52 The cardiovascular safety of Drv has also been studied through postmarketing analysis comparing its effects on endothelial cell function with those of other PIs. Drv has been shown to have minimal or no effect on induction of endothelial oxidative stress and inflammation (ie, phosphorylation of p65/RelA-NFκB) compared to atazanavir and lopinavir. 53 Secretion of soluble ICAM or VCAM has been shown not to be significantly altered by Drv or Drv-Rtv. 53 Similar results were observed regarding senescence markers, such as senescence-associated β-galactosidase activation and overexpression of phospho-p53, p16 INK4 , p21 WAF1 , and prelamin A. 53 Instead, interestingly, an intermediate effect of Atv-Rtv and a strong effect of lopinavir-Rtv on all these inflammation and endothelial activation markers has been demonstrated. 53 Evaluation of cardiovascular risk associated with Drv-Rtv has produced conflicting results, both in randomized clinical trials and observational studies. In the MONARCH trial, 54 no effect on endothelial function (measured by flow-mediated dilation) was observed when switching from a standard ART regimen to Drv/Rtv monotherapy or to Drv-Rtv + a combination of nucleoside reverse-transcriptase inhibitors. Data from the DAD study showed a markedly increased incidence of cardiovascular events associated with Drv-Rtv in a cohort of 35,711 patients with a median follow-up of 7 years. 55 Furthermore, recent unpublished data based on CVD events in postmarketing pharmacovigilance databases conducted on 5,721 patients enrolled in 19 Janssen-sponsored clinical trials did not indicate an increased risk of CVD events with Drv-Rtv use in treatment duration up to 6 years, although a significantly higher rate of cardiovascular events in patients receiving Drv 600-Rtv 100 mg twice daily vs Drv 800-Rtv 100 mg once daily was observed. 56 Data on cardiovascular events in patients on Drv-Cobi-FTC-Taf are scarce: neither the EMERALD nor the AMBER study reported a significant incidence of such adverse events. 45, 46 Further studies are needed to evaluate the long term safety of this compound and to ascertain the unlikely association of Drv with cardiovascular events. Few studies have directly addressed Drv and Cobi bone toxicity/safety. It is possible to approximate Drv and Cobi bone safety profiles by examining the results of the NEAT trial, which compared Drv-Rtv + raltegravir to Drv-Rtv + TDF-FTC at 48 weeks: differences in bone-mineral density (BMD) changes were more pronounced in the TDF-containing regimen, where significant increases in serum markers of bone turnover were observed. 57, 58 A recent study evaluated impact on bone by Drv-Cobi-FTC and TDF/Taf. At week 48, a better BMD profile was reported in the Taf group: compared to the TDF group, more patients had an increase in BMD at the hip or spine (5% and 11% for Taf vs 0 and 2% for TDF, respectively), and fewer patients had decreased BMD at the hip or spine (18% and 33% for Taf vs 62% and 55% for TDF, respectively). Interestingly, an AIDS Clinical Trials Group (ACTG) A5257 substudy found similar BMD loss among regimens with different PIs, such as Atv-Rtv and Drv-Rtv, but lower in patients receiving raltegravir. Of note, all subjects in the two PI arms received TDF, and because Rtv coadministra- 
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Drv-Cobi-Ftc-Taf some of the effects described might have to be related to enhanced TDF exposition, rather than to a direct effect of PIs on bone. 59, 60 Conversely, data from ACTG A5224s showed a similar PI effect (Atv-Rtv) with either TDF-FTC or abacavir-lamivudine. 61 The recently published EMERALD study had a boneinvestigation substudy investigating the efficacy and safety of switching to a single-tablet Drv-Cobi-FTC-Taf regimen vs continuing a regimen of boosted PI plus TDF-FTC. The substudy reported a BMD increase at the hip, lumbar spine, and femoral neck at week 48 in the study group (P,0.0001 for ANCOVA within-treatment comparison at hip and lumbar spine and P=0.029 for femoral neck). Conversely, in the control group, at week 48 hip BMD was stable, whereas lumbar spine and femoral neck BMD had decreased (P=0.78 for ANCOVA within-treatment comparison at the hip, P=0.98 for lumbar spine, and P=0.34 for femoral neck). Moreover, ANCOVA comparison among treatments showed P,0.0001 for the hip and lumbar spine and P=0.004 for the femoral neck. 45 In the AMBER study, 46 better bone profiles were observed in patients on Drv-Cobi-FTC-Taf vs Drv-Cobi-FTC-TDF, with a significantly minor decrease in spine and neck BMD. All these observations point to a good safety profile of Drv and Cobi in terms of bone metabolism. Liver toxicity was reported in 0.5% of patients on treatment with Drv. Due to its pharmacokinetic characteristics (Drv and Cobi are metabolized mainly by the liver) and in consideration of data on hepatic safety, Drv is contraindicated in patients with severe hepatic impairment and severe liver insufficiency. 62 Central nervous system adverse events have rarely been reported (,1%) in randomized clinical trials involving experienced 45 and naïve patients. 46 
Taf-FTC safety
Many clinical trials have documented the safety and efficacy of Taf in treatment-naïve and experienced adults in combination with other FDCs. 5, 6, 63 These studies observed improvements in median changes of estimated eGFR at week 48 in the switch groups. Median urine protein at week 48 decreased more in the switch groups compared to the control group. No cases of proximal renal tubulopathy or Fanconi syndrome were observed. Fasting lipid values increased from baseline in the switch groups, with no statistically significant changes in total cholesterol:HDL ratio. 5, 6, 63 BMD measured by dual-energy X-ray absorptiometry increased in the switch groups and remained stable or decreased in the control groups, showing a good bone safety profile for Taf compared to TDF.
An interesting meta-analysis 64 can summarize the aforementioned observations. It identified not only significantly smaller reductions in eGFR-Crocroft-Gault (CG), smaller changes in Retinol Binding Protein (RBP):creatinine (Cr) and urine β 2 microglobulin:Cr ratio, and less reduction in spine and hip BMD in treatment-naïve patients but also significant efficacy advantages of improved renal function and BMD. These included significant decreases in urine albumin:Cr, urine protein:Cr, urine RBP:Cr, and urine β 2 microglobulin:Cr ratios and increases in hip and spine BMD by 1.47% and 1.56%, respectively, compared with continued TDF regimens. Moreover, in this analysis a higher viral suppression rate in patients switching to Taf was observed. 64 This observation was recently reinforced in a randomized, active-controlled, multicenter, open-label trial that confirmed the superiority of Taf vs TDF in virological efficacy. 7 Finally, a recent study remarked that since coadministration with Cobi results in significantly higher Tfv concentrations and higher TDF discontinuation compared to other antiretroviral regimens, registration trials of Taf 65 may have been prone to bias when evaluating safety comparisons with Taf.
Conclusion
Drv-Cobi-FTC-Taf is a drug regimen with demonstrated efficacy in HIV infection. The safety and tolerability of this combination is comparable to other STRs available at this time. PIs maintain a role in treatment of HIV infection, especially in naïve patients when an ART regimen needs to be initiated as soon as possible and resistance tests and HLA-B5701 are not available, as well as in experienced patients, when virological failure to nonnucleoside reversetranscriptase inhibitors or integrase strand-transfer inhibitor is demonstrated and an STR with a high genetic barrier and low-toxicity profile is required.
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